Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms.

Authors: Pierangeli, Silvia S; Chen, Pojen P; Raschi, Elena; Scurati, Silvia; Grossi, Claudia; Borghi, Maria Orietta; Palomo, Ivan; Harris, E Nigel; Meroni, Pier Luigi

Published In Semin Thromb Hemost, (2008 Apr)

Abstract: Antiphospholipid antibodies (Abs) are associated with thrombosis and are a risk factor for recurrent pregnancy loss and obstetric complications in patients with the antiphospholipid syndrome. It is generally accepted that the major autoantigen for aPL Abs is beta (2) glycoprotein I, which mediates the binding of aPL Abs to target cells (i.e., endothelial cells, monocytes, platelets, trophoblasts, etc.) leading to thrombosis and fetal loss. This article addresses molecular events triggered by aPL Abs on endothelial cells, platelets, and monocytes and complement activation, as well as a review of the current knowledge with regard to the putative receptor(s) recognized by aPL Abs on target cells as well as novel mechanisms that involve fibrinolytic processes. A section is devoted to the description of thrombotic and inflammatory processes that lead to obstetric complications mediated by aPL Abs. Based on experimental evidence using in vitro and in vivo models, new targeted therapies for treatment and/or prevention of thrombosis and pregnancy loss in antiphospholipid syndrome are proposed.

PubMed ID: 18720303 Exiting the NIEHS site

MeSH Terms: Abortion, Habitual/etiology; Abortion, Habitual/physiopathology; Antibodies, Antiphospholipid/immunology*; Antiphospholipid Syndrome/blood; Antiphospholipid Syndrome/etiology; Antiphospholipid Syndrome/immunology*; Antiphospholipid Syndrome/physiopathology; Autoantigens/immunology; Blood Platelets/immunology; Blood Platelets/physiology; Complement Activation; Endothelial Cells/immunology; Endothelial Cells/physiology; Female; Fibrinolysis; Humans; Inflammation Mediators/physiology; Monocytes/immunology; Monocytes/physiology; Placenta/pathology; Pregnancy; Pregnancy Complications, Hematologic/blood; Pregnancy Complications, Hematologic/etiology; Pregnancy Complications, Hematologic/physiopathology; Thrombin/physiology; Thrombophilia/blood; Thrombophilia/etiology; Thrombophilia/physiopathology; Thromboplastin/physiology; Trophoblasts/immunology; Trophoblasts/pathology; Venous Thrombosis/blood; Venous Thrombosis/etiology; Venous Thrombosis/physiopathology; beta 2-Glycoprotein I/immunology

to Top